Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](Sarepta Therapeutics, Inc.)"
Count: 44
Selected: 0
| NCT ID | Title |
|---|
| NCT05881408 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 (Delandistrogene Moxeparvovec) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | ||
| NCT05876780 | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) | ||
| NCT05096221 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD) | ||
| NCT04626674 | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD) | ||
| NCT04475926 | A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, and LGMD2C/R5, ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice | ||
| NCT04004065 | Two-Part Study for Dose Determination of SRP-5051 (Vesleteplirsen) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment | ||
| NCT03992430 | A Study to Compare Safety and Efficacy of a High Dose of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) | ||
| NCT03985878 | A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995) | ||
| NCT03769116 | A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 (Delandistrogene Moxeparvovec) for Duchenne Muscular Dystrophy (DMD) | ||
| NCT03675126 | An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen) | ||
| NCT03652259 | Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency) | ||
| NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | ||
| NCT03375255 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD) | ||
| NCT03375164 | A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD) | ||
| NCT03218995 | Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping | ||
| NCT02710500 | rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies | ||
| NCT02530905 | Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients | ||
| NCT02500381 | Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) | ||
| NCT02420379 | Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy | ||
| NCT02310906 | Phase I/II Study of SRP-4053 in DMD Patients | ||
| NCT02286947 | Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy | ||
| NCT02255552 | Study of Eteplirsen in DMD Patients | ||
| NCT01976091 | A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D) | ||
| NCT01593072 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers | ||
| NCT01566877 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers | ||
| NCT01540409 | Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy | ||
| NCT01396239 | Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients | ||
| NCT01375985 | Safety Study of Single Administration Intravenous Treatment for Influenza | ||
| NCT01353040 | Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus | ||
| NCT01353027 | Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus | ||
| NCT00844597 | Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients | ||
| NCT00451256 | Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG) | ||
| NCT00387283 | Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020 | ||
| NCT00381433 | Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid | ||
| NCT00343148 | Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid | ||
| NCT00248066 | Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries | ||
| NCT00244647 | A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis | ||
| NCT00229749 | Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients | ||
| NCT00091845 | An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease | ||
| NCT04708314 | An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy | ||
| NCT04179409 | A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD Duplications | ||
| NCT00159250 | Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy | ||
| NCT03680365 | Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families | ||
| NCT03655223 | Early Check: Expanded Screening in Newborns |
